{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:22:08Z","timestamp":1780557728086,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Foundation of South Africa","award":["106035"],"award-info":[{"award-number":["106035"]}]},{"name":"National Research Foundation of South Africa","award":["108571"],"award-info":[{"award-number":["108571"]}]},{"name":"National Research Foundation of South Africa","award":["111678"],"award-info":[{"award-number":["111678"]}]},{"name":"Wellcome Trust Intermediate Fellowship in Public Health and Tropical Medicine","award":["211360\/Z\/18\/Z"],"award-info":[{"award-number":["211360\/Z\/18\/Z"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.018","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T18:41:29Z","timestamp":1576521689000},"page":"1291-1301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4132-1922","authenticated-orcid":false,"given":"Chukwudi A.","family":"Nnaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8776-4737","authenticated-orcid":false,"given":"Muki S.","family":"Shey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4608-3951","authenticated-orcid":false,"given":"Olatunji O.","family":"Adetokunboh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-4779","authenticated-orcid":false,"given":"Charles S.","family":"Wiysonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.018_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1741-7015-6-3","article-title":"Yellow fever control in Cameroon: where are we now and where are we going?","volume":"6","author":"Wiysonge","year":"2008","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2019.12.018_b0010","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0140-6736(16)30195-7","article-title":"Yellow fever vaccine supply: a possible solution","volume":"387","author":"Monath","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.018_b0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2019.12.018_b0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.12.018_b0025","doi-asserted-by":"crossref","first-page":"5751","DOI":"10.1016\/j.vaccine.2017.06.087","article-title":"WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper - June 2013","volume":"35","author":"World Health O","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vaccine.2014.05.040","article-title":"Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013\u2013recommendations","volume":"33","author":"World Health Organization (WHO)","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0035","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1084\/jem.20072290","article-title":"Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine","volume":"204","author":"Norrby","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.12.018_b0040","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/511869","article-title":"Yellow fever: epidemiology and prevention","volume":"44","author":"Barnett","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.018_b0045","unstructured":"Hickling J, Jones R. Yellow fever vaccination: The potential of dose sparing to increase vaccine supply and availability. A Technical Programme Report for Programme for Appropriate Technology in Health (PATH) Report. 2013. Available via https:\/\/www.path.org\/publications\/files\/TS_vtg_yf_rpt.pdf Accessed on 29 December 2017."},{"key":"10.1016\/j.vaccine.2019.12.018_b0050","unstructured":"World Health Organization (WHO). Fractional Dose Yellow Fever Vaccine as a Dose-sparing Option for Outbreak Response. WHO Secretariat Information Paper. Department of Immunization, Vaccines and Biologicals. WHO reference number: WHO\/YF\/SAGE\/16.1. Published 20 July 2016. Available via: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246236\/WHO-YF-SAGE-16.1-eng.pdf;jsessionid=F4BD11CEBB8426D52C781267F9795A8A?sequence=1 21 April 2018."},{"key":"10.1016\/j.vaccine.2019.12.018_b0055","unstructured":"World Health Organization (WHO). WHO supports the immunization of 874 000 people against yellow fever in Nigeria. News Release. 16 October 2017. Available via http:\/\/www.who.int\/mediacentre\/news\/releases\/2017\/immunization-yellowfever-nigeria\/en\/ Accessed on 27 December 2017."},{"key":"10.1016\/j.vaccine.2019.12.018_b0060","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.vaccine.2007.01.047","article-title":"Meta-analyses in vaccinology","volume":"25","author":"Jacobson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2288-5-14","article-title":"The strengths and limitations of meta-analyses based on aggregate data","volume":"5","author":"Lyman","year":"2005","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.12.018_b0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0895-4356(94)00096-9","article-title":"A statistician looks at met-analysis","volume":"48","author":"Finney","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2019.12.018_b0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"key":"10.1016\/j.vaccine.2019.12.018_b0080","first-page":"g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.vaccine.2019.12.018_b0085","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.12.018_b0090","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.16-0401","article-title":"A meta-analysis of serological response associated with yellow fever vaccination","volume":"95","author":"Jean","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.12.018_b0095","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.vaccine.2013.10.050","article-title":"How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?","volume":"31","author":"Thomas","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0100","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","article-title":"Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review","volume":"29","author":"Thomas","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0105","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.2147\/DDDT.S99600","article-title":"Yellow fever vaccine-associated viscerotropic disease: current perspectives","volume":"10","author":"Thomas","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.vaccine.2019.12.018_b0110","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0115","unstructured":"Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org."},{"key":"10.1016\/j.vaccine.2019.12.018_b0120","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.vaccine.2019.12.018_b0125","unstructured":"The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). RevMan [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014."},{"key":"10.1016\/j.vaccine.2019.12.018_b0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2019.12.018_b0135","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.vaccine.2019.12.018_b0140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/1471-2334-14-391","article-title":"Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline","volume":"14","author":"Campi-Azevedo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.018_b0145","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study","volume":"9","author":"Martins","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.12.018_b0150","doi-asserted-by":"crossref","first-page":"e1993","DOI":"10.1371\/journal.pone.0001993","article-title":"Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial","volume":"3","author":"Roukens","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.12.018_b0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0092-1157(88)90034-0","article-title":"Studies on yellow fever vaccine. III\u2013Dose response in volunteers","volume":"16","author":"Lopes Ode","year":"1988","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2019.12.018_b0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0092-1157(77)80003-6","article-title":"Stabilized 17D strain yellow fever vaccine: dose response studies, clinical reactions and effects on hepatic function","volume":"5","author":"Freestone","year":"1977","journal-title":"J Biol Stand"},{"key":"10.1016\/j.vaccine.2019.12.018_b0165","first-page":"113","article-title":"Field studies of the immune response to 17D yellow fever virus","volume":"38","author":"Fox","year":"1943","journal-title":"Am J Hyg."},{"key":"10.1016\/j.vaccine.2019.12.018_b0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/M18-1529","article-title":"Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial","volume":"169","author":"Roukens","year":"2018","journal-title":"Ann Internal Med"},{"key":"10.1016\/j.vaccine.2019.12.018_b0175","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1016\/j.vaccine.2018.05.041","article-title":"Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study","volume":"36","author":"de Menezes","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0180","doi-asserted-by":"crossref","unstructured":"Nzolo D, Engo Biongo A, Lusakibanza M, et al. Safety profile of fractional dosing of yellow fever vaccine, experience from community based pharmacovigilance in Kinshasa, DRC; 2017.","DOI":"10.1016\/j.vaccine.2018.08.052"},{"key":"10.1016\/j.vaccine.2019.12.018_b0185","article-title":"Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Preliminary Report","author":"Ahuka-Mundeke","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.018_b0190","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/j.vaccine.2009.02.049","article-title":"Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy","volume":"27","author":"Roukens","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0195","doi-asserted-by":"crossref","first-page":"taw045-taw","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u201313","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2019.12.018_b0200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0205","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2007.04.060","article-title":"Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Sejvar","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0210","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.018_b0215","unstructured":"World Health Organization. Global norms and standards for biological quality, safety and efficacy. Proceeding. 23: 12-15 Available via http:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/yellow_fever\/ECBS%202008%20WHO_TRS%20872%20%20Amndmt_Yellow%20Fever.pdf Accessed on 29 June 2018. Vol 23. 1 ed: World Health Organization:12-5."},{"key":"10.1016\/j.vaccine.2019.12.018_b0220","unstructured":"World Health Organization (WHO). Expert Committee on Biological Stadardization. Requirements for Yellow Fever Vaccine (Requirements for Biological Substances No. 3) Proposed Amendment Geneva, October 2008."},{"key":"10.1016\/j.vaccine.2019.12.018_b0225","doi-asserted-by":"crossref","first-page":"e27753","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.12.018_b0230","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2019.12.018_b0235","unstructured":"Domingo C, Fraissinet J, Ansah PO, et al. Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study. The Lancet Infectious Diseases."},{"key":"10.1016\/j.vaccine.2019.12.018_b0240","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/S0034-89102004000500009","article-title":"Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial","volume":"38","author":"Camacho","year":"2004","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.vaccine.2019.12.018_b0245","unstructured":"Gavi. Yellow Fever Supply and Procurement Roadmap. Update 20th March 2017. Available from: https:\/\/www.gavi.org\/...\/supply-procurement\/yellow-fever-roadmap-public-summary\/ Accessed on 11 July 2018."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:39:52Z","timestamp":1759401592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316603"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}